[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553553":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":19,"locations":28,"responsibleParty":47,"collaborators":49,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":18,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":18,"enrollmentInfo":63,"targetDuration":18,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":30,"whyStopped":18,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Maryland St. Joseph Medical Center","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Study Drug Arm - Angiotensin II arm","Angiotensin II",[12],"Drug: Angiotensin II",[14],{"type":15,"name":10,"description":16,"armGroupLabels":17,"otherNames":18},"DRUG","Angiotensin II: Starting dose of 2.5 ng\u002Fkg\u002Fmin administered IV; may dose escalate up to 80 ng\u002Fkg\u002Fmin in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng\u002Fkg\u002Fmin in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng\u002Fkg\u002Fmin every 2 minutes.",[9],null,[20,25],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Aja Janyavula","CONTACT","410-427-5459","ajanyavula@umm.edu",{"name":26,"role":22,"phone":23,"phoneExt":18,"email":27},"Sam Rudow","samuel.rudow@umm.edu",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Towson","Maryland","21204","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-76.60191,39.4015,{"lat":40,"lon":39},[43,44],{"name":26,"role":22,"phone":23,"phoneExt":18,"email":27},{"name":45,"role":46,"phone":18,"phoneExt":18,"email":18},"Rawn Salenger, MD","PRINCIPAL_INVESTIGATOR",{"type":48,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[50],{"name":51,"class":52},"La Jolla Pharmaceutical Company","INDUSTRY","100553553","phase-4-ang-first-trial-angiotensin-ii-as-first-line-vasopressor-therapy-in-cardiac-surgery-100553553",false,"NCT06487585","ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)","Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery (ANG-First Trial)","Inclusion Criteria:\n\n* Adult patients ≥ 18 years of age undergoing cardiac surgery requiring CPB\n* Patients must have clinical features of vasodilation as determined by a MAP \\\u003C 65 mmHg that is non-transient in the opinion of the treating physician\n* Patients must be adequately volume resuscitated in the opinion of the treating physician\n* Systemic Vascular Resistance index (SVRi) \\\u003C 1970 dynes·sec\u002Fcm⁵\u002Fm² to support the clinical diagnosis of vasodilation; if no pulmonary artery catheter is in place, vasodilatory hypotension diagnosis according to the judgement of the critical care team\n* Biventricular systolic function is at or greater than pre-cardiopulmonary bypass baseline as demonstrated by echocardiographic evaluation, or the patient is concomitantly treated with\n\nExclusion Criteria:\n\n* Bleeding as primary etiology of hypotension, as determined by \\> 4 units RBC transfusion in 24 hours.\n* Patients on ECMO\n* Patients with active endocarditis\n* Patients already on renal replacement therapy or creatinine of \\> 4 mg\u002Fdl within 2 weeks of surgery\n* Patients with contraindications to Angiotensin II including women who are pregnant or breastfeeding or have active coronary ischemia, mesenteric ischemia, limb ischemia, or high potassium (\\> 5.5 meq\u002FL) while receiving Angiotensin II",true,"ALL","18 Years",{"count":64,"type":65},100,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.",[71],"Vasodilatory Hypotension During or After Cardiac Surgery",[73,74,75,76],"Vasodilation","Hypotension","Cardiopulmonary Bypass","Cardiac Surgery","2025-12-18",{"date":79,"type":80},"2025-12-22","ACTUAL",{"date":82,"type":80},"2025-05-06",{"date":84,"type":65},"2026-02",{"name":5,"class":6},1]